Journal
VACCINES
Volume 9, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/vaccines9070732
Keywords
human norovirus; acute gastroenteritis; HuNoV vaccine; VLPs; culture system
Categories
Funding
- National Natural Science Foundation of China [31700151, 81772192]
- National Mega-Projects against Infectious Diseases [2018ZX10301406-002]
- China Postdoctoral Science Foundation [2015M582364]
- State Key Laboratory of Virology [2021IOV003, klv-2016-02]
Ask authors/readers for more resources
HuNoV is the leading cause of AGE worldwide, but the development of its vaccine faces challenges due to the lack of a robust in vitro cultivation system. Although HuNoV vaccine candidates based on VLPs are being tested in clinical trials, overcoming challenges to achieve broad protection remains unresolved.
Human norovirus (HuNoV) is the leading cause of acute gastroenteritis (AGE) worldwide, which is highly stable and contagious, with a few virus particles being sufficient to establish infection. Although the World Health Organization in 2016 stated that it should be an absolute priority to develop a HuNoV vaccine, unfortunately, there is currently no licensed HuNoV vaccine available. The major barrier to the development of an effective HuNoV vaccine is the lack of a robust and reproducible in vitro cultivation system. To develop a HuNoV vaccine, HuNoV immunogen alone or in combination with other viral immunogens have been designed to assess whether they can simultaneously induce protective immune responses against different viruses. Additionally, monovalent and multivalent vaccines from different HuNoV genotypes, including GI and GII HuNoV virus-like particles (VLPs), have been assessed in order to induce broad protection. Although there are several HuNoV vaccine candidates based on VLPs that are being tested in clinical trials, the challenges to develop effective HuNoV vaccines remain largely unresolved. In this review, we summarize the advances of the HuNoV cultivation system and HuNoV vaccine research and discuss current challenges and future perspectives in HuNoV vaccine development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available